2-氨基-4,6-二氯-S-三嗪 | 933-20-0

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 中文名称: 2-氨基-4,6-二氯-S-三嗪
• 中文别名: 2-氨基-4,6-二氯-1,3,5-三嗪；2-氨基-4,6-二氯三嗪
• 英文名称: 4,6-dichloro-1,3,5-triazin-2-amine
• 英文别名: 2-amino-4,6-dichloro-[1,3,5]triazine；2-Amino-4,6-dichloro-S-triazine
• CAS: 933-20-0
• 化学式: C₃H₂Cl₂N₄
• mdl: MFCD00078331
• 分子量: 164.982
• InChiKey: MCLXKFUCPVGZEN-UHFFFAOYSA-N

物化性质

• 熔点：
  239-242°C
• 沸点：
  428.8±28.0 °C(Predicted)
• 密度：
  1.731±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO、甲醇（少量）
• 稳定性/保质期：
  | 稳定性 | 保持稳定 |

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险类别码：
  R20/21/22
• 海关编码：
  2933699090
• 安全说明：
  S23,S36/37/39
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -20°C冷冻存储，置于惰性气氛中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-4,6-dichlorotriazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-4,6-dichlorotriazine
CAS number: 933-20-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C3H2Cl2N4
Molecular weight: 165.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

2-氨基-4,6-二氯-S-三嗪是一种杂环有机化合物，可用作医药中间体。

反应信息

• 作为反应物：
  描述：

  2-氨基-4,6-二氯-S-三嗪 在 铁粉 silica gel 作用下， 以 gaseous matrix 为溶剂， 生成 甲烷
  参考文献：
  名称：

  Preparation of aligned carbon nanotubes catalysed by laser-etched cobalt thin films

  摘要：

  Pyrolysis of 2-amino-4,6-dichloro-s-triazine over laser-etched thin films of cobalt deposited on an inverted silica substrate generates aligned bundles and films of carbon nanotubes of uniform dimensions. Scanning electron microscopy, high resolution transmission electron microscopy, energy dispersive X-ray analyses, electron energy loss spectroscopy and electron diffraction studies reveal that the aligned tubes, which usually grow perpendicular to the substrate surface, are mainly straight (length less than or equal to 100 mu m; 30-50 nm OD), contain traces of nitrogen (< 5%) and exhibit a preferred helicity (e.g. armchair 25-30%). Other graphitic structures (e.g. polyhedral particles, encapsulated particles and amorphous carbon) are absent. Energised cobalt clusters/particles (less than or equal to 50 nm), ablated during laser-etching, may condense and recrystallise evenly on the surface of the substrate as cobalt and/or cobalt oxide. These crystals apparently play a key role in nanotube production. (C) 1998 Elsevier Science B.V.

  DOI：

  10.1016/s0009-2614(98)00093-1
• 作为产物：
  描述：

  三聚氯氰 在 氨 作用下， 以 水 、 丙酮 为溶剂， 以93%的产率得到2-氨基-4,6-二氯-S-三嗪
  参考文献：
  名称：

  N-甲基三聚氰胺：合成，表征和物理性质

  摘要：

  作为生产改性三聚氰胺甲醛树脂和其他聚合物构件的有价值的化合物，N-甲基三聚氰胺最近已变得越来越重要。这些聚合物的一大优点是减少了致癌的甲醛。选择聚合过程（例如，物质聚合，溶液中的聚合）并控制聚合反应和这些新型材料的性能，需要了解用作新结构单元的三聚氰胺衍生物的性能。N的所有可能排列制备了甲基三聚氰胺，并通过GC / MS监测反应进程。制备2,4,6-Tris（二甲基氨基）-1,3,5-三嗪以完成该系列；然而，这也是各种合成路线中可能的副产物。优化反应条件以获得具有尽可能高纯度的每种衍生物的高产率。通过NMR和IR光谱，质谱，元素分析和单晶X射线衍射对这些物质进行表征。另外，测定了物理性质，例如溶解度，熔点和p K b值。氨基，甲基氨基和二甲基氨基的数目对这些性质具有显着影响。总而言之，我们发现通过增加氨基和甲基氨基的数量，溶解度和p Kb增加。随着氨基数目的增加，化合物趋于形成氢键，因此，熔点转移至它们开始分解的较高温度范围。

  DOI：

  10.1021/acs.joc.6b00355
• 作为试剂：
  描述：

  1-苯并呋喃-2-乙胺 在 碳酸氢钠 作用下， 以 2-氨基-4,6-二氯-S-三嗪 、 水 、 丙酮 为溶剂， 以95%的产率得到2-chloro-4-amino-6-(1'-(2'-benzofuranyl)ethylamino)-s-triazine
  参考文献：
  名称：

  Triazine derivatives, and herbicides containing the derivatives as the

  摘要：

  一种三嗪衍生物，其通式表示为：##STR1## 或通式表示为：##STR2## （其中X.sup.1表示氢原子、卤素原子、具有1至4个碳原子的烷基或具有1至4个碳原子的烷氧基，Z表示氧原子或硫原子，R.sup.1表示具有1至4个碳原子的烷基，R.sup.2表示卤素原子、具有1至4个碳原子的烷硫基或具有1至4个碳原子的烷氧基）。本发明还提供了一种有效制备上述三嗪衍生物的方法和一种含有上述三嗪衍生物作为除草有效成分的除草剂。

  公开号：

  US04740230A1

文献信息

• Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites
  作者：Alessandro Baliani、Valerie Peal、Ludovic Gros、Reto Brun、Marcel Kaiser、Michael P. Barrett、Ian H. Gilbert

  DOI：10.1039/b813394h

  日期：——

  Human African trypanosomiasis (HAT), caused by the protozoan parasite Trypanosoma brucei spp., is a major health problem in sub-Saharan Africa. New drugs are urgently required for the disease. Selective uptake of toxic compounds into trypanosomes has been achieved by exploiting plasma membrane transporters. For example, the P2 aminopurine transporter, along with other transporters, selectively concentrates melamine and benzamidine moieties into trypanosomes. We have previously reported the use of the melamine motif to selectively target nitrofuran to the trypanosome. In this paper we report the further investigation of the structure activity relationships and the effect of the introduction of different functionalized substituents onto the melamine unit. Most of the compounds tested in vitro for their trypanocidal activity showed activities in the submicromolar range against T. b. rhodesiense.

  人类非洲锥虫病（HAT），由原生动物寄生虫布氏锥虫引起，是撒哈拉以南非洲地区的一个主要健康问题。该疾病急需新药。通过利用细胞膜转运蛋白，已经实现了将毒性化合物选择性摄取进入锥虫体内。例如，P2氨基嘌呤转运蛋白以及其他转运蛋白，能够将蜜胺和苄胺基团选择性聚集到锥虫体内。我们之前报道了利用蜜胺基序选择性靶向硝呋喃至锥虫的方法。在本篇论文中，我们进一步研究了结构活性关系，并探究了将不同功能化取代基引入蜜胺单元的影响。大部分在体外测试的化合物对罗德西亚布氏锥虫显示出亚微摩尔级别的杀锥虫活性。
• MK2 INHIBITORS AND USES THEREOF
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20160075720A1

  公开（公告）日：2016-03-17

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• [EN] NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES<br/>[FR] NOUVEAUX COMPOSÉS COMME STIMULANTS RESPIRATOIRES POUR LE TRAITEMENT DE TROUBLES OU DE MALADIES DE CONTRÔLE DE LA RESPIRATION
  申请人：GALLEON PHARMACEUTICALS INC

  公开号：WO2012074999A1

  公开（公告）日：2012-06-07

  The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

  本发明涵盖了用于治疗患有呼吸控制疾病或紊乱的受试者的组合物。本发明还包括一种治疗患有呼吸系统疾病或紊乱的受试者的方法，包括向受试者施用本发明的药物配方的治疗有效量。本发明还包括一种预防或稳定患有呼吸节律不稳定的受试者的方法，包括向受试者施用本发明的药物配方的治疗有效量。
• [EN] RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER<br/>[FR] INHIBITEURS DU RÉCEPTEUR DE LA TYROSINE KINASE POUR LE TRAITEMENT DE MALADIE OU DE TROUBLE SENSIBLE À LA MODULATION DE LA PROTÉINE KINASE
  申请人：US HEALTH

  公开号：WO2021050900A1

  公开（公告）日：2021-03-18

  Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the abnormal activity or expression of the Eph receptor tyrosine kinase. The inhibitors are particularly useful for treating colorectal cancer.

  Ephrin类型受体酪氨酸激酶抑制剂，也被称为Eph酪氨酸激酶受体抑制剂，用于治疗癌症、炎症性疾病、自身免疫疾病或部分特征为Eph受体酪氨酸激酶异常活性或表达的退行性疾病。这些抑制剂特别适用于治疗结直肠癌。
• NOVEL TRIAZINE DERIVATIVE
  申请人：Carna Biosciences, Inc.

  公开号：EP2824099A1

  公开（公告）日：2015-01-14

  To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I) : wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturated 5- to 6-membered ring, thereby forming a multiply fused ring, or a pharmaceutically acceptable salt thereof.

  提供以下式(I)所代表的一种新型三嗪衍生物： 由以下式(I)表示的三嗪衍生物： 其中 R1代表取代或未取代的芳基、取代或未取代的杂环基、取代或未取代的杂环融合环或取代或未取代的炔基， R2代表氢原子、卤原子、取代或未取代的较低烷基或取代或未取代的烷氧基， R3代表取代或未取代的芳基、取代或未取代的杂环基或取代或未取代的杂环融合环， R4代表氢原子、取代或未取代的较低烷基、取代或未取代的烷氧基、取代或未取代的氨基或卤原子，以及 R5代表氢原子、取代或未取代的较低烷基，或R1和R5可结合形成饱和或不饱和的5-至6元环，从而形成多重融合环， 或其药学上可接受的盐。